GLP-1 RA treatment was associated with a significant reduction in the risk of 10 cancers, including esophageal, colorectal, endometrial, gallbladder, kidney, liver, ovarian, and pancreatic cancers, as well as meningioma and multiple myeloma, compared to insulin-treated patients. This evidence concerns the gene INS and cancer.